LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: A Confirmed Case of Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Miami, Florida, USA.

    Warp, Peyton V / Hauschild, Maia / Tookes, Hansel E / Ciraldo, Katrina / Serota, David P / Cruz, Irasema

    Research square

    2023  

    Abstract: Background: Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the street drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who inject drugs ...

    Abstract Background: Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the street drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who inject drugs (PWID). This case is unique because it is the first case to our knowledge describing wound care for a xylazine-induced wound with a confirmatory xylazine test strip (XTS) in the setting of a syringe services program (SSP) and in the state of Florida.
    Case presentation: A 43-year-old woman with a past medical history of severe opioid use disorder and stimulant use disorder presented to a student-run clinic at the IDEA Miami SSP for wound care. She had multiple ulcerations diffusely over her bilateral forearms with surrounding erythema and warmth. Seven weeks later, she presented to clinic again for wound care because her wounds had progressed. At this visit, a XTS was used to confirm the presence of xylazine in her urine. Wound care management and harm reduction strategies employed at both visits are discussed below. Wound outcomes are unknown as the patient has not returned to clinic.
    Conclusions: Many PWID at highest risk for acute and chronic health consequences of xylazine-adulterated fentanyl do not have access to healthcare outside of low barrier clinics and SSPs due to lack of insurance or mistrust of the traditional healthcare system. There is an urgent need for access to XTS for PWID and clinical practice guidelines for the treatment of xylazine-related wounds in outpatient clinics.
    Language English
    Publishing date 2023-07-26
    Publishing country United States
    Document type Preprint
    DOI 10.21203/rs.3.rs-3194876/v1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A confirmed case of xylazine-induced skin ulcers in a person who injects drugs in Miami, Florida, USA.

    Warp, Peyton V / Hauschild, Maia / Serota, David P / Ciraldo, Katrina / Cruz, Irasema / Bartholomew, Tyler S / Tookes, Hansel E

    Harm reduction journal

    2024  Volume 21, Issue 1, Page(s) 64

    Abstract: Background: Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the illicit drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who use drugs ( ... ...

    Abstract Background: Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the illicit drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who use drugs (PWUD). This case is unique because it is the first case to our knowledge describing wound care for a xylazine-induced wound with a confirmatory xylazine test strip (XTS) in the setting of a syringe services program (SSP) and in the state of Florida.
    Case presentation: A 43-year-old woman with a past medical history of severe opioid use disorder and stimulant use disorder presented to a student-run clinic at a Miami SSP for wound care. She had multiple ulcerations diffusely over her bilateral forearms with surrounding erythema and warmth. Seven weeks later, she presented to clinic again for wound care because her wounds had progressed. At this visit, a XTS was used to confirm the presence of xylazine in her urine. Wound care management and harm reduction strategies employed at both visits were informed by best clinical judgement due to lack of formal guidelines at the time. Wound outcomes are unknown as the patient has not returned to clinic.
    Conclusions: Many PWUD at highest risk for acute and chronic health consequences of xylazine-adulterated fentanyl do not have access to healthcare outside of low barrier clinics and SSPs due to lack of insurance or mistrust of the traditional healthcare system due to stigma. There is an urgent need for access to XTS for PWUD and clinical practice guidelines for the treatment of xylazine-related wounds in outpatient clinics.
    MeSH term(s) Female ; Humans ; Adult ; Xylazine/adverse effects ; Florida ; Skin Ulcer ; Fentanyl/adverse effects ; Harm Reduction ; Drug Overdose ; Analgesics, Opioid
    Chemical Substances Xylazine (2KFG9TP5V8) ; Fentanyl (UF599785JZ) ; Analgesics, Opioid
    Language English
    Publishing date 2024-03-15
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 2146691-9
    ISSN 1477-7517 ; 1477-7517
    ISSN (online) 1477-7517
    ISSN 1477-7517
    DOI 10.1186/s12954-024-00978-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Improving access to HIV care among people who inject drugs through tele-harm reduction: a qualitative analysis of perceived discrimination and stigma.

    Scaramutti, Carolina / Hervera, Belén / Rivera, Yanexy / Chueng, Teresa A / Forrest, David W / Suarez, Edward / Serota, David P / Alkamli, Hatoun / Ciraldo, Katrina / Bartholomew, Tyler S / Tookes, Hansel E

    Harm reduction journal

    2024  Volume 21, Issue 1, Page(s) 50

    Abstract: Background: Tele-harm reduction (THR) is a telehealth-enhanced, peer-led, harm reduction intervention delivered within a trusted syringe services program (SSP) venue. The primary goal of THR is to facilitate linkage to care and rapid, enduring virologic ...

    Abstract Background: Tele-harm reduction (THR) is a telehealth-enhanced, peer-led, harm reduction intervention delivered within a trusted syringe services program (SSP) venue. The primary goal of THR is to facilitate linkage to care and rapid, enduring virologic suppression among people who inject drugs (PWID) with HIV. An SSP in Miami, Florida, developed THR to circumvent pervasive stigma within the traditional healthcare system.
    Methods: During intervention development, we conducted in-depth interviews with PWID with HIV (n = 25) to identify barriers and facilitators to care via THR. We employed a general inductive approach to transcripts guided by iterative readings of the raw data to derive the concepts, themes, and interpretations of the THR intervention.
    Results: Of the 25 PWID interviewed, 15 were in HIV care and adherent to medication; 4 were in HIV care but non-adherent; and 6 were not in care. Themes that emerged from the qualitative analysis included the trust and confidence PWID have with SSP clinicians as opposed to professionals within the traditional healthcare system. Several barriers to treatment were reported among PWID, including perceived and actual discrimination by friends and family, negative internalized behaviors, denial of HIV status, and fear of engaging in care. Facilitators to HIV care included empathy and respect by SSP staff, flexibility of telehealth location, and an overall destigmatizing approach.
    Conclusion: PWID identified barriers and facilitators to receipt of HIV care through the THR intervention. Interviews helped inform THR intervention development, centered on PWID in the destigmatizing environment of an SSP.
    MeSH term(s) Humans ; Substance Abuse, Intravenous/complications ; Substance Abuse, Intravenous/therapy ; Health Services Accessibility ; Harm Reduction ; Perceived Discrimination ; Drug Users ; HIV Infections/complications ; HIV Infections/therapy
    Language English
    Publishing date 2024-02-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 2146691-9
    ISSN 1477-7517 ; 1477-7517
    ISSN (online) 1477-7517
    ISSN 1477-7517
    DOI 10.1186/s12954-024-00961-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Opportunities for cancer prevention at syringe services programs: acceptability of HPV self-sampling and vaccination among people who inject drugs.

    Hinkes, Samuel / Ciraldo, Katrina / Kobetz, Erin / Bartholomew, Tyler S / Rinehart, Sarah / Siringo, Nicolette / Barnett, Rebecca / Godbole, Neha / Jeanty, Frantzia / Frederick, Morgan / Tookes, Hansel E

    Harm reduction journal

    2024  Volume 21, Issue 1, Page(s) 70

    Abstract: Introduction: Despite having a high risk of acquiring sexually transmitted infections, people who inject drugs (PWID) often do not receive recommended HPV screenings due to barriers to healthcare. Guideline-based cervical HPV screening and vaccination ... ...

    Abstract Introduction: Despite having a high risk of acquiring sexually transmitted infections, people who inject drugs (PWID) often do not receive recommended HPV screenings due to barriers to healthcare. Guideline-based cervical HPV screening and vaccination can prevent cervical cancer. Low-cost, low-barrier methods for cancer screening and prevention are important for vulnerable communities such as PWID.
    Methods: We examined acceptability of HPV self-sampling at a syringe services program (SSP). Participants with a cervix (n = 49) participated in patient education followed by a survey to assess willingness to perform HPV self-sampling versus standard of care.
    Results: 59% found self-sampling to be acceptable, citing privacy, ease, and quickness. Among those opting for HPV screening delivered by a provider (n = 16), participants cited concerns about adequate sampling (81%) and test accuracy (75%). Notably, only 18% of participants reported complete HPV vaccination.
    Conclusion: Cervical HPV self-sampling was acceptable to PWID. SSP-based efforts to provide preventative health services could place tools for cancer screening into the hands of PWID, a need-to-reach community.
    MeSH term(s) Female ; Humans ; Substance Abuse, Intravenous ; Drug Users ; Papillomavirus Infections/prevention & control ; Papillomavirus Infections/diagnosis ; Uterine Cervical Neoplasms/prevention & control ; Uterine Cervical Neoplasms/diagnosis ; Vaccination ; Patient Acceptance of Health Care
    Language English
    Publishing date 2024-03-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2146691-9
    ISSN 1477-7517 ; 1477-7517
    ISSN (online) 1477-7517
    ISSN 1477-7517
    DOI 10.1186/s12954-024-00982-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.

    Bartholomew, Tyler S / Plesons, Marina / Serota, David P / Alonso, Elizabeth / Metsch, Lisa R / Feaster, Daniel J / Ucha, Jessica / Suarez, Edward / Forrest, David W / Chueng, Teresa A / Ciraldo, Katrina / Brooks, Jimmie / Smith, Justin D / Barocas, Joshua A / Tookes, Hansel E

    Addiction science & clinical practice

    2024  Volume 19, Issue 1, Page(s) 21

    Abstract: Background: People who inject drugs (PWID) remain a high priority population under the federal Ending the HIV Epidemic initiative with 11% of new HIV infections attributable to injection drug use. There is a critical need for innovative, efficacious, ... ...

    Abstract Background: People who inject drugs (PWID) remain a high priority population under the federal Ending the HIV Epidemic initiative with 11% of new HIV infections attributable to injection drug use. There is a critical need for innovative, efficacious, scalable, and community-driven models of healthcare in non-stigmatizing settings for PWID. We seek to test a Comprehensive-TeleHarm Reduction (C-THR) intervention for HIV prevention services delivered via a syringe services program (SSP).
    Methods: The CHARIOT trial is a hybrid type I effectiveness-implementation study using a parallel two-arm randomized controlled trial design. Participants (i.e., PWID; n = 350) will be recruited from a syringe services program (SSP) in Miami, Florida. Participants will be randomized to receive either C-THR or non-SSP clinic referral and patient navigation. The objectives are: (1) to determine if the C-THR intervention increases engagement in HIV prevention (i.e., HIV pre-exposure prophylaxis; PrEP or medications for opioid use disorder; MOUD) compared to non-SSP clinic referral and patient navigation, (2) to examine the long-term effectiveness and cost-effectiveness of the C-THR intervention, and (3) to assess the barriers and facilitators to implementation and sustainment of the C-THR intervention. The co-primary outcomes are PrEP or MOUD engagement across follow-up at 3, 6, 9 and 12 months. For PrEP, engagement is confirmed by tenofovir on dried blood spot or cabotegravir injection within the previous 8 weeks. For MOUD, engagement is defined as screening positive for norbuprenorphine or methadone on urine drug screen; or naltrexone or buprenorphine injection within the previous 4 weeks. Secondary outcomes include PrEP adherence, engagement in HCV treatment and sustained virologic response, and treatment of sexually transmitted infections. The short and long term cost-effectiveness analyses and mixed-methods implementation evaluation will provide compelling data on the sustainability and possible impact of C-THR on comprehensive HIV prevention delivered via SSPs.
    Discussion: The CHARIOT trial will be the first to our knowledge to test the efficacy of an innovative, peer-led telehealth intervention with PWID at risk for HIV delivered via an SSP. This innovative healthcare model seeks to transform the way PWID access care by bypassing the traditional healthcare system, reducing multi-level barriers to care, and meeting PWID where they are.
    Trial registration: ClinicalTrials.gov NCT05897099. Trial registry name: Comprehensive HIV and Harm Prevention Via Telehealth (CHARIOT). Registration date: 06/12/2023.
    MeSH term(s) Humans ; Drug Users ; Harm Reduction ; HIV Infections/epidemiology ; HIV Infections/prevention & control ; Methadone/urine ; Randomized Controlled Trials as Topic ; Substance Abuse, Intravenous/complications
    Chemical Substances Methadone (UC6VBE7V1Z)
    Language English
    Publishing date 2024-03-25
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2492632-2
    ISSN 1940-0640 ; 1940-0640
    ISSN (online) 1940-0640
    ISSN 1940-0640
    DOI 10.1186/s13722-024-00447-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.

    Suarez, Edward / Bartholomew, Tyler S / Plesons, Marina / Ciraldo, Katrina / Ostrer, Lily / Serota, David P / Chueng, Teresa A / Frederick, Morgan / Onugha, Jason / Tookes, Hansel E

    Annals of medicine

    2023  Volume 55, Issue 1, Page(s) 733–743

    Abstract: Background: ...

    Abstract Background:
    MeSH term(s) Humans ; Harm Reduction ; Retrospective Studies ; Pharmaceutical Preparations ; Buprenorphine ; Drug Users ; Substance Abuse, Intravenous ; Opioid-Related Disorders
    Chemical Substances Pharmaceutical Preparations ; Buprenorphine (40D3SCR4GZ)
    Language English
    Publishing date 2023-03-01
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1004226-x
    ISSN 1365-2060 ; 1651-2219 ; 0785-3890 ; 1743-1387
    ISSN (online) 1365-2060 ; 1651-2219
    ISSN 0785-3890 ; 1743-1387
    DOI 10.1080/07853890.2023.2182908
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Availability of medications for opioid use disorder in outpatient and inpatient pharmacies in South Florida: a secret shopper survey.

    Syros, Alina / Rodriguez, Maria G / Rennick, Andrew C / Dima, Grace A / Gibstein, Alexander R / de la Parte, Lauren / Hermenau, Matthew G / Ciraldo, Katrina J / Chueng, Teresa A / Tookes, Hansel E / Bartholomew, Tyler S / Serota, David P

    Addiction science & clinical practice

    2022  Volume 17, Issue 1, Page(s) 63

    Abstract: Background: Despite the proven efficacy of medications for opioid use disorder (MOUD) and recent reduction in barriers to prescribers, numerous obstacles exist for patients seeking MOUD. Prior studies have used telephone surveys to investigate pharmacy- ... ...

    Abstract Background: Despite the proven efficacy of medications for opioid use disorder (MOUD) and recent reduction in barriers to prescribers, numerous obstacles exist for patients seeking MOUD. Prior studies have used telephone surveys to investigate pharmacy-related barriers to MOUD. We applied this methodology to evaluate inpatient and outpatient pharmacy barriers to MOUD in South Florida.
    Methods: Randomly selected pharmacies in South Florida (Miami-Dade, Broward, and Palm Beach Counties) were called using a standardized script with a "secret shopper" approach until 200 successful surveys had been completed. The primary outcome was the availability of any buprenorphine products. Second, a list of all 48 acute care hospitals within the aforementioned counties was compiled, and hospitals were contacted by telephone using a second structured script.
    Results: A total of 1374 outpatient pharmacies and 48 inpatient pharmacies were identified. 378 randomly selected outpatient pharmacies were contacted to accrue 200 successful calls (53% success rate). All 48 inpatient pharmacies were contacted to successfully complete 25 inpatient surveys (52%). Of the 200 outpatient pharmacies contacted, 38% had any buprenorphine available. There was a significant difference in buprenorphine availability by county, with Miami-Dade having the least availability and Palm Beach having the most availability (27% vs. 47%, respectively; p = 0.04). Of the 38% with buprenorphine available, 82% had a sufficient supply for a two-week prescription of buprenorphine 8 mg twice daily. Of the pharmacies that did not have buprenorphine, 55% would be willing to order with a median estimated time to receive an order of 2 days (IQR 1.25-3 days). Of the 25 surveyed inpatient pharmacies, 88% reported having buprenorphine on inpatient formulary, and 55% of hospitals had at least one restriction on ordering of buprenorphine beyond federal regulations.
    Conclusions: The results of this study highlight significant pharmacy-related barriers to comprehensive OUD treatment across the healthcare system including both acute care hospital pharmacies and outpatient community pharmacies. Despite efforts to increase the number of MOUD providers, there still remain downstream obstacles to MOUD access.
    MeSH term(s) Humans ; Buprenorphine/supply & distribution ; Florida ; Inpatients ; Opioid-Related Disorders/drug therapy ; Outpatients ; Pharmacies
    Chemical Substances Buprenorphine (40D3SCR4GZ)
    Language English
    Publishing date 2022-11-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 2492632-2
    ISSN 1940-0640 ; 1940-0640
    ISSN (online) 1940-0640
    ISSN 1940-0640
    DOI 10.1186/s13722-022-00346-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top